drugset / Trial / NCT01649258
Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy
Phase 1
Terminated
29 enrolled
University of Southern California
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelSupportive care
Summary
This clinical trial studies how well fosaprepitant dimeglumine and granisetron transdermal system work in preventing nausea and vomiting in patients with breast cancer undergoing chemotherapy. Antiemetic drugs may help lessen or prevent nausea and vomiting in patients treated with chemotherapy
Timeline
- Start
- 2012-09-04
- Primary completion
- 2017-05-22
- Completion
- 2017-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fosaprepitant | Other / unclassified | — | Intravenous |
| Subject | Granisetron | Other / unclassified | — | Other |